Notably, our findings are
consistent with an experimental study recently performed by Koh et al,27 who found that rosuvastatin is more potent and
less hydrophilic than pravastatin and is associated with adverse metabolic effects, including increases in insulin
resistance and glycosylated hemoglobin; conversely, pravastatin proved to be safe by decreasing these 2 parameters.
In agreement with our findings, the Irish Health Services Executive Primary Care Reimbursement Services national
pharmacy claims database28 demonstrated that rosuvastatin was associated with the highest increase in new-onset DM
compared with other statins